BUCHANG PHARMA(SH:603858) Hua Er Jie Jian Wen·2025-12-29 11:13Group 1 - The transaction involves the subsidiary Luzhou Buchang signing an exclusive supply agreement with Malaysian company MEDISPEC for the drug Efparepoetin alfa [1] - MEDISPEC will act as the exclusive agent in Malaysia, responsible for the registration, promotion, distribution, and sales of the product [1] - The agreement is valid for 10 years from the date of obtaining the import license, with a potential 5-year extension for good performance [1] Group 2 - The product, Efparepoetin alfa, is aimed at treating anemia in chronic kidney disease dialysis patients and is classified as a Class I new biological drug with no similar products approved in China [1] - The company has invested approximately 512 million yuan in research and development as of September 30, 2025 [1] - A listing application for the product has already been submitted [1] Group 3 - MEDISPEC is responsible for the product registration and will bear the associated costs, while Luzhou Buchang will provide technical support [1] - Intellectual property rights for the product remain with Luzhou Buchang [1] - The agreement is governed by Chinese law, with disputes to be submitted to the Hong Kong International Arbitration Centre [1]